Login / Signup

Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.

Deli WangElaine Kearney KowalewskiGary Koch
Published in: Therapeutic innovation & regulatory science (2022)
Aβ plaques removal in the brain due to amyloid therapy is strongly correlated with a better clinical response in patients with early Alzheimer's disease and a higher ARIA-E rate for the treatment groups and clinical trials in this meta-analysis. These relationships suggest that the balance between the clinical efficacy response and safety in ARIA-E rate is relevant for the choice of doses for amyloid therapies in confirmatory clinical trials.
Keyphrases
  • clinical trial
  • systematic review
  • meta analyses
  • cognitive decline
  • phase ii
  • open label
  • case control
  • phase iii
  • resting state
  • cerebral ischemia
  • mild cognitive impairment